Figures
Abstract
Introduction
We previously reported that alveolar macrophages from patients with chronic obstructive pulmonary disease (COPD) are defective in their ability to phagocytose apoptotic cells, with a similar defect in response to cigarette smoke. The exact mechanisms for this defect are unknown. Sphingolipids including ceramide, sphingosine and sphingosine-1-phosphate (S1P) are involved in diverse cellular processes and we hypothesised that a comprehensive analysis of this system in alveolar macrophages in COPD may help to delineate the reasons for defective phagocytic function.
Methods
We compared mRNA expression of sphingosine kinases (SPHK1/2), S1P receptors (S1PR1-5) and S1P-degrading enzymes (SGPP1, SGPP2, SGPL1) in bronchoalveolar lavage-derived alveolar macrophages from 10 healthy controls, 7 healthy smokers and 20 COPD patients (10 current- and 10 ex-smokers) using Real-Time PCR. Phagocytosis of apoptotic cells was investigated using flow cytometry. Functional associations were assessed between sphingosine signalling system components and alveolar macrophage phagocytic ability in COPD. To elucidate functional effects of increased S1PR5 on macrophage phagocytic ability, we performed the phagocytosis assay in the presence of varying concentrations of suramin, an antagonist of S1PR3 and S1PR5. The effects of cigarette smoking on the S1P system were investigated using a THP-1 macrophage cell line model.
Results
We found significant increases in SPHK1/2 (3.4- and 2.1-fold increases respectively), S1PR2 and 5 (4.3- and 14.6-fold increases respectively), and SGPL1 (4.5-fold increase) in COPD vs. controls. S1PR5 and SGPL1 expression was unaffected by smoking status, suggesting a COPD “disease effect” rather than smoke effect per se. Significant associations were noted between S1PR5 and both lung function and phagocytosis. Cigarette smoke extract significantly increased mRNA expression of SPHK1, SPHK2, S1PR2 and S1PR5 by THP-1 macrophages, confirming the results in patient-derived macrophages. Antagonising SIPR5 significantly improved phagocytosis.
Citation: Barnawi J, Tran H, Jersmann H, Pitson S, Roscioli E, Hodge G, et al. (2015) Potential Link between the Sphingosine-1-Phosphate (S1P) System and Defective Alveolar Macrophage Phagocytic Function in Chronic Obstructive Pulmonary Disease (COPD). PLoS ONE 10(10): e0122771. https://doi.org/10.1371/journal.pone.0122771
Editor: Dominik Hartl, University of Tübingen, GERMANY
Received: October 26, 2014; Accepted: February 19, 2015; Published: October 20, 2015
Copyright: © 2015 Barnawi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the manuscript.
Funding: This work was supported by a National Health and Medical Research Council Project Grant (SH, HJ, RH, RM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Cigarette smoking is a major cause of COPD, yet despite the huge campaign that encourages smoking cessation worldwide, the smoking incidence is only slowly decreasing in developed countries and still increasing in developing countries. COPD is an incurable disease and currently available treatments are largely ineffective [1,2]. There is therefore an urgent need for further understanding the pathophysiology of COPD to advise effective new therapies.
In previous studies our group has shown that alveolar macrophages from COPD patients are defective in their ability to phagocytose apoptotic cells despite smoking cessation (defective efferocytosis) [3–7]. We and others have shown that if these apoptotic cells are not cleared effectively by alveolar macrophages, they may undergo secondary necrosis which can further promote the inflammation in the lung [8,9]. We have also shown that both alveolar macrophages and monocyte-derived macrophages from COPD patients are impaired in their ability to phagocytose bacteria which might potentially contribute to bacterial colonization in COPD [10]. Numerous molecules have been identified as possible contributors to these macrophage phenomena in COPD [11], but the exact mechanism is yet unknown.
Sphingolipid metabolites including ceramide, sphingosine andsphingosine-1-phosphate (S1P) are involved in diverse cellular processes. Phosphorylation of sphinosine by the sphingosine kinases (SPHKs) results in the production of S1P, while its acetylation by ceramide synthase produces ceramide, and then sphingomyelin after sphingomyelin synthase catalysed coupling to phosphocholine. Structural changes in these molecules have been proven to result in modulation of cellular function [11]. Many sphingolipid molecules have been linked to inflammatory lung diseases and used as potential therapeutic targets, such as acid sphingomyelinase in acute lung injury [12], neutral sphingomyelinase-2 in COPD [13], and ceramide in cystic fibrosis [14].
We have previously shown that human lung tissue comprises a complex expression profile for the individual components of the S1P signalling system including synthesising enzymes, receptors and degrading enzymes [15]. In COPD we found correlations between mRNA expression levels of several receptors and enzymes involved in the S1P signalling system in the lung suggesting common regulatory mechanisms. However, we did not assess individual lung cells such as alveolar macrophages, which are likely to be of importance in COPD. S1P is one of the most important sphingolipid molecules and its role in immune cell function has been shown in many studies [16,17]. It has been shown to be involved in a multitude of cellular signalling pathways and responses, such as proliferation, survival and growth [18] and exerts its function through five G-protein coupled receptors (S1PR1-5) [19].
The alveolar macrophage is a very interesting target for our investigations since it has been shown that S1P regulates macrophage function, phagosome maturation and migration [20]. The phagocytic function of macrophages has also been shown to be modulated by the sphingosine system; for example, it has been shown that phagocytosis of M.tuberculosis bacteria depends on SPHK1 [21]. S1P which has been implicated in macrophage actin assembly and phagosome function [22] was shown to improve phagocytosis of Cryptococcus neoformans when exogenously added to wild-type alveolar macrophages [23]. Furthermore, ceramide, the precursor of S1P, has an opposing role to S1P and has been found to decrease macrophage efferocytosis in COPD [24]. Taken together, these studies suggest that defective efferocytosis in alveolar macrophages in COPD may be associated with the S1P system. Despite the numerous studies on this system and its role in inflammation and diseases, to the best of our knowledge, there have been no comprehensive studies of the S1P system in macrophages from healthy controls, or of the role of this system in the defective macrophage function in COPD. In this study, we compared the expression of components of the S1P-signalling system in alveolar macrophages from healthy control volunteers and COPD patients. We determined the expression profiles of SPHK1, SPHK2, receptors (S1PR1-5) and the S1P-degrading enzymes, sphingosine-1-phosphate phosphatase 1 and 2 (SGPP1 and SGPP2) and sphingosine-1-phosphate lyase 1 (SGPL1) and their correlation with the ability of alveolar macrophages to phagocytose apoptotic cells. We further investigated functional consequences of smoking on the expression profile of the S1P system in current- or ex-smoking COPD subjects and by using an in vitro THP-1 macrophage cell line model.
Material and Methods
Categorization of patients
This study was approved by the Royal Adelaide Hospital Ethics Committee (Adelaide, Australia) and informed written consent was obtained for each subject in this study. Patients were categorized based on gender, smoking status, age, the presence of lung cancer and lung function (Table 1). The diagnosis of COPD was carried out according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standards. Any subject who had ceased smoking within the previous 6 months was included in the ‘current smoker’ groups. Exclusion criteria included diagnosis of other inflammatory lung diseases, blood malignancy and current infection.
Bronchoalveolar lavage (BAL) and isolation of macrophages
Bronchoscopy was performed according to American Thoracic Society recommendations for the performance of bronchoscopy for investigative purposes, as previously described [25]. BAL was collected then centrifuged at 1600 RPM for 5 min and the supernatant frozen for later use. Macrophages were isolated by adhering to plastic as previously described, concentration adjusted to 4×10(5) cells/ml [3] then either used for phagocytosis or frozen immediately at -80°C for gene expression analysis.
Cell culture and stimulation
THP-1monocytes (ATCC, Manassas, VA, USA) were differentiated into macrophages by seeding the cells at a density of 4×10(5) cells/mL in 24 well plastic plates, then stimulating with 100nM phorbol 12-myristate 13-acetate [26] in RPMI 1640 medium at 37°C with 5% CO2 for 72 has previously described [27]. Experiments were carried out between passages 6 and 20.
Exposure of THP-1 macrophages to cigarette smoke extract was carried as previously described [4,5,28,29]. After cigarette smoke extract exposure, non-adherent cells were discarded, and adherent cells were incubated with 500μL cold PBS for 5 min, then harvested by scraping the adherent cells with a plastic scraper into a 1.5 mL tubes prior to centrifugation at 4°C at 1600 RPM. Supernatant was removed and cell pellet stored at– 80°C for mRNA expression analysis.
Reverse transcription and quantitative real-time PCR (qPCR)
The total RNA was extracted from snap frozen alveolar macrophages or THP-1 macrophages using the RNeasy Mini Kit (Qiagen, Doncaster, Australia) according to the manufacturer’s instructions. The concentration of total RNA was determined using standard photospectometry. The RNA quality expressed as RIN number was determined using the RNA Pico-Chip and Agilent 2100 Bioanalyzer (Agilent Technologies, Forest Hill, Australia). Complementary DNA (cDNA) was synthesized using RT2 HT First Strand Kit (Qiagen). Synthesized cDNA was stored at −20°C. The qPCR analyses of the samples were performed using Custom RT2 Profiler PCR arrays (Qiagen) and the ABI sequence detection system (StepOne Plus) as previously described [15], with modifications. Briefly, a 25μL reaction mixture into 96 well plates coated with primer pairs directed against components of the S1P system (SPHK1, SPHK2, S1P receptors (S1PR1, S1PR2, S1PR3, S1PR4, S1PR5) and the S1P-degrading enzymes SGPP1, SGPP2 and SGPL1. Three reference genes, glucose 6-phosphate dehydrogenase (G6PD), hypoxanthine phosphoribosyl transferase 1 (HPRT1) and ribosomal protein L13a (RPL13A) were used in the array for data normalization. The efficiency and reliability of the PCR reaction was assessed by determining the efficiency of the reverse transcriptase reaction by Reverse-transcription control (RTC) determining, the efficiency of polymerase chain reaction itself by positive PCR control (PPC), and DNA contamination in the reaction by genomic DNA control (HGDC).
Functional associations between sphingosine signalling system components and alveolar macrophage phagocytic ability in COPD
Phagocytosis of apoptotic cells was measured as previously reported [3,4,30]. Briefly, 16HBE bronchial epithelial cell targets were maintained in continuous culture, induced to apoptosis using UV, then labelled with sytox orange (Molecular Probes, Oregon, USA). The apoptotic cells were incubated with macrophages at a ratio of 10:1 for 1.5h. Non-adhered cells were removed and macrophages removed by gentle pipetting, following 5min incubation with 500uL ice-cold phosphate buffered saline (PBS). Macrophages that had ingested apoptotic cells were stained with CD13 phycoerythrin cyanine-7 (PE-Cy7) (BD Biosciences, San Jose CA, USA)), autofluorescence was quenched with trypan blue and 30,000 total events per tube were acquired immediately using a FACSCanto II Flow Cytometer (BD Biosciences). Macrophages were identified based on autofluorescence properties and staining with CD13. The percentage of the macrophages ingesting apoptotic cells was recorded.
To further elucidate functional effect of increased S1PR5 on macrophage phagocytic ability, we performed the phagocytosis assay in the presence of varying concentrations of Suramin (Sigma Aldrich, Castle Hill, NSW, Australia), an antagonist of S1PR3 and S1PR5 [31]. Suramin at concentrations of 10nM to 10μM was added for 30min prior to the phagocytosis assay.
Statistical analysis
Analysis was performed using SPSS statistic software (SPSS Inc. IBM Chicago, USA) and the two-sample Wilcoxon rank sum test, or the Kruskal-Wallis test for analyses of more than two groups. Correlation with lung function, smoking, age, gender and presence of lung cancer on mRNA expression levels of SPHK/S1P system genes were determined using data from all subjects and Pearson’s correlation coefficient with significance set at p<0.05.
Results
Characterization of expression profile of the S1P system in alveolar macrophages in healthy subjects
The mRNA expression levels of the components of the S1P system in alveolar macrophages from healthy individuals are unknown. We therefore compared the relative mRNA expression levels of the SPHK/S1P system genes in alveolar macrophages obtained from healthy control subjects (n = 10, Fig 1). All components of the S1P system were expressed in alveolar macrophages. We found no significant difference in the relative mRNA expression levels between the S1P synthesizing enzymes, SPHK1 and2. In contrast, the S1P degradation enzymes, SGPP1, SGPP2 and SPGL1 were differentially expressed. SGPP1 showed the highest, while SGPP2 had the lowest relative expression level. There were large differences in relative-mRNA expression levels among S1P receptors, with S1PR4 being the predominant subtype while S1PR5 showed the lowest expression level. The rank order of mRNA expression levels of all receptors from the high to low was S1PR4>S1PR2>S1PR1>S1PR3>S1PR5.
Box plots present median ± 25th and 75th percentiles (solid box) with the 10th and 90th percentiles shown by whiskers outside the box. The Ct values were subtracted from 20, so that higher values represent higher mRNA expression levels.
Characterization of expression profile of the sphingosine system in alveolar macrophages in COPD
There was significantly higher mRNA-expression of both SPHK1&SPHK2 in alveolar macrophages from COPD patients (3.5 and 2.1fold increase respectively) compared to healthy controls (Fig 2). To assess the effect of smoking, the expression of SPHK was assessed in alveolar macrophages of healthy current smokers and current- or ex- smoker COPD patients. Compared to non-smoking individuals, a significantly higher relative mRNA expression of SPHK1 was found in current healthy smokers (6-fold increase) and current-smoker COPD patients (4.8-fold increase) compared to control subjects (Fig 2A). Significantly higher mRNA expression levels for SPHK2 were also found in current healthy smokers (4.4-fold increase) and current-smoker COPD subjects (2.3-fold increase) (Fig 2B). No significant changes in SPHK1 or SPHK2 expression were found in ex-smoker COPD patients, consistent with an effect of smoke rather than COPD disease on the relative expression levels of this SPHK isoform in alveolar macrophages.
(A) Significantly higher mRNA expression of SPHK1 was noted in current healthy smokers (6-fold increase), current smoker COPD (4.8-fold increase) and total COPD (3.5-fold increase) compared to control subjects (*p<0.05 vs control). No significant increase of SPHK1 was found in alveolar macrophages isolated from ex-smoker COPD patients. (B) Significantly higher mRNA expression of SPHK2 in current healthy smokers (4.4-fold increase), current smoker COPD(2.3-fold increase) and in the total COPD group (2.1-fold increase) versus control subjects (*p<0.05 vs control) was found. No significant increase in SPHK2 was found in ex-smoker COPD subjects compared to control subjects. Data presented as box plots as described in Fig 1. The Ct values were subtracted from 20 so that higher values mean higher mRNA expression levels. Data presented as box plots as described in Fig 1. The Ct values were subtracted from 20 so that higher values represent higher mRNA expression levels.
Significantly higher mRNA expression levels for S1PR2 and S1PR5 were present in alveolar macrophages from COPD subjects (4.3 and 14.6 fold increase respectively) compared to healthy controls (Fig 3). No significant differences were found between S1PR1, S1PR3 and S1PR4 and healthy controls (data not shown).
(A) Significantly higher mRNA expression levels of S1PR2 in current healthy smokers (9.3-fold increase), current smoker COPD subjects (6.1-fold increase) and in the total COPD group (4.3-fold increase) versus control subjects (*p<0.05 vs control) was found. No significant increase of S1PR2 was found in ex-smoker COPD patients compared to control subjects. (B) Significantly higher mRNA expression of S1PR5 was noted in in ex-smoker COPD subjects (32-fold increase), current smoker COPD subjects (5.4-fold increase) and in the COPD group (14.6-fold increase) versus healthy control subjects (*p<0.05 vs control). Data presented as box plots as described in Fig 1. The Ct values were subtracted from 20 so that higher values mean higher mRNA expression levels.
To assess the effect of smoking, the expression of S1P receptors was assessed in alveolar macrophages from healthy current smokers and current- or ex- smoker COPD patients. We found significantly higher mRNA expression for S1PR2 in the healthy current smokers (9.3-fold increase p<0.05 vs control) and current-smoker COPD patients (6.1-fold increase p<0.05 vs control) compared to healthy controls (Fig 3A). Interestingly, no difference was found between ex-smoker COPD subjects and control subjects. In contrast, we observed significantly higher S1PR5 mRNA levels in alveolar macrophages from both current- and ex-smoker COPD patients compared to control subjects (n = 10, p<0.05 vs control, Fig 3B). The basal very low S1PR5 expression was 32-fold higher in alveolar macrophages from ex-smoker COPD patients and 5.4-fold higher from current-smoker COPD subjects compared to health controls. In addition there was no difference in the relative S1PR5 expression levels between healthy smokers and non-smokers (Fig 3B), suggesting a COPD disease-specific effect rather than a cigarette smoke effect. No difference was found in S1PR1, S1PR3 and S1PR4 mRNA expression in healthy current smokers and current- or ex- smoker COPD patients compared to healthy controls (data not shown).
Significantly higher mRNA expression of SGPL1 was found in COPD alveolar macrophages compared to cells from control subjects (4.5-fold increase p<0.05 COPD vs. control, Fig 4A). No significant differences were found between groups for either SGPP1 or SGPP2 (Fig 4B and 4C. However when we split the COPD on the basis of their smoking status we found significantly higher expression of SGPP2 mRNA in alveolar macrophages from current-smoker COPD subjects compared to healthy control subjects (6.1-fold increase p<0.05 vs control, Fig 4). In contrast, no significant differences were found in SGPP2 expression in either the ex-smoker COPD group or, healthy current smokers vs. healthy non-smoking controls.
(A) Significantly higher mRNA expression of SGPL1 in COPD patients (4.5-fold increase) versus control subjects (*p<0.05 vs control). No significant increase of SGPL1was found in current smoker COPD, ex-smoker COPD or healthy current smokers. (B) Significantly higher mRNA expression levels of SGPP2 in current smoker COPD patients (6.1-fold increase) versus control subjects (*p<0.05 vs control) was noted. No significant increase of SGPP2 was found in ex-smoker COPD subjects or healthy current smokers Data presented as box plots as described in Fig 1. The Ct values were subtracted from 20 so that higher values mean higher mRNA expression levels.
A non-significant trend toward higher expression of SGPL1 mRNA was found in healthy current smokers (p = 0.08) and in both ex-smoker and current-smoker COPD subjects (p = 0.06 for both) compared to control subjects. No significant differences were found in relative mRNA expression for SGPP1 between healthy current smokers, ex-smoker COPD subjects and current smoker COPD subjects compared to control subjects (Data not shown).
Functional associations between S1P signalling system components and alveolar macrophage phagocytic ability in COPD
To assess the functional relevance of our findings with regard to macrophage phagocytic function we investigated the association between phagocytosis and expression pattern of the S1P signalling system components. Consistent with our previous reports [3–7], a significantly reduced ability to phagocytose apoptotic cells was observed in alveolar macrophages from COPD patients in comparison to healthy control macrophages (mean±SEM, COPD 12.62±2.43% vs controls 20.98±1.98% p = 0.004, Fig 5A. For 13 COPD subjects, a strong negative correlation was found between SPHK1, S1PR3 and S1PR5 mRNA expression levels and the ability of alveolar macrophages to phagocytose apoptotic cells (SPHK1 r = -0.59, p<0.05; S1PR3 r = -0.70, p<0.05; S1PR5 r = -0.87 p<0.05; SPHK1 data presented in Fig 5B. No significant associations were found between the presence of lung cancer and macrophage phagocytic ability (r = -0.471, p = 0.098).
(A) Phagocytosis of apoptotic 16HBE airway epithelial cells (AEC) by alveolar macrophages from chronic obstructive pulmonary disease (COPD) subjects and controls. Compared to alveolar macrophages from healthy controls, macrophages from COPD patients had a significantly reduced ability to phagocytose apoptotic 16HBE epithelial cells (*p<0.05 vs control). (B) Correlation between the relative mRNA expression of SPHK1 and % efferocytosis. There was a significant correlation between efferocytosis and mRNA expression of SPHK1 (p<0.05). The correlation coefficients are listed in the results.
Phagocytosis of apoptotic cells was dose dependently increased by the addition of the S1PR3 and S1PR5 agonist Suramin, with a maximum effect at a concentration of 1uM (Fig 6).
To further elucidate functional effect of increased S1PR5 on macrophage phagocytic ability, we performed the phagocytosis assay in the presence of varying concentrations of Suramin, an antagonist of S1PR3 and S1PR5. Suramin at concentrations of 10nM to 10μM were added for 30 min prior to the phagocytosis assay. We noted a significant (p<0.05) increase in phagocytosis of apoptotic cells in the presence of Suramin.
Associations between S1P signalling system components in alveolar macrophages
Since the components of the SPHK/S1P system are part of a combined signalling system, we analysed correlations between expressions of the various components. A strong positive correlation between the relative mRNA expression levels was observed for SPHK1 and SPHK2 (r = 0.62, p<0. 05) (Fig 7A. In addition a strong positive correlation was found between S1P receptor subtypes e.g. S1PR1 and S1PR5 (r = 0.55, p<0.05); S1PR2 and S1PR4 (r = 0.79, p<0.05; Fig 7B & 7C. We also noted a strong positive correlation between SPHK1 and S1PR2 (r = 0.81, p<0.05). There were positive correlations between the S1P degradation enzymes; SGPP1 significantly correlated with SGPP2 (r = 0.38, p<0.05) (Fig 7D; SGPL1 significantly correlated with both SGPP1 and SGPP2 (r = 0.60, p<0.05 and r = 0.54, p<0.05 respectively; Fig 7E & 7F).
(A) correlation between SPHK1 and 2, p<0.05; (B) correlation between S1PR1 and S1PR5, p<0.05; (C) correlation between S1PR2 and S1PR4, p<0.05; (D) correlation between SGPP1 and SGPP2 p<0.05; (E) correlation between SGPL1 and SGPP1 p<0.05; (F) SGPL1 and SGPP2. The correlation coefficients are listed in the results.
Associations between S1P signalling system components and fev1, fev1/fvc, smoking status, pack years, age, gender, presence of cancer, type of cancer and previous or ongoing chemotherapy and/or radiotherapy
A strong negative correlation was found between lung function (fev1) and mRNA expression levels of SPHK1, S1PR1, S1PR3 and S1PR5 in alveolar macrophages (SPHK1 r = -0.49, p<0.05; S1PR1 r = -0.44 p<0.05; S1PR3, r = -0.45, p<0.05; S1PR5 r = -0.55, p<0.05; Fig 8), with a trend observed for both SGPL1 and SGPP2 with fev1 (SGPL1 r = -0.32, p = .078; SGPP2 r = -0.37, p = .091; Fig 8). Furthermore a negative correlation was observed between the fev1/fvc ratio, a further indicator of lung function, and mRNA expression levels of S1PR5 and S1PR3 (S1PR5 r = -0.61 p<0.05; S1PR3 r = -0.52 p<0.05), with a trend observed between SPHK1 and fev1/fvc (r = -0.33, p = .063).
Significant (p<0.05) correlations were found between fev1 and (A) SPHK1 (B) S1PR1 (C) S1PR3, (D) S1PR5, p<0.05. The correlation coefficients are listed in the results.
We found a significant positive correlation between smoking status and relative mRNA expression levels of both SPHK isoforms, S1PR2, S1PR4 and SGPP2 (SPHK1r = 0.41, p<0.05; SPHK2 r = 0.38, p<0.05; S1PR2 r = 0.36, p<0.05, S1PR4 r = 0.35, p<0.05; SGPP2 r = 0.39, p<0.05). There were significant positive correlations between age and mRNA expression levels of S1PR1 and S1PR3 (S1PR1 r = 0.39, p<0.05; S1PR3 r = 0.45, p<0.05). Moreover a high positive correlation was revealed between mRNA expression levels of SPHK2 and S1PR5 and smoking pack years (SPHK2 r = 0.36, p<0. 05; S1PR5 r = 0.54, p<0. 05). No correlation was found between gender and any of the S1P system mRNA levels. The only significant correlation between the presence of cancer and S1P system mRNA expression levels was for S1PR3 that showed a positive correlation with the presence of cancer independent of COPD status(r = 0.41, p<0.05). Moreover, no significant associations were found between S1P system mRNA expression levels with types of lung cancer or exposure to chemotherapy and/or radiotherapy.
Investigation of the effect of cigarette smoke extract on the expression of SPHK1, SPHK2, S1PR2, S1PR5 and SGPP2 in THP-1 macrophages in vitro
Assessment of S1P system genes showed variation according to their passages, with expression pattern comparable to normal human alveolar macrophages between passages 6 to 20. To confirm the effects of cigarette smoke on macrophage expression of SPHK1, SPHK2, S1PR2, S1PR5 and SGPP2 we determined the expression levels of the SPHK/S1P system in THP-1 macrophages exposed to 10% cigarette smoke extract for 24h. Consistent with the alveolar macrophages from human smoker COPD subjects, we noted significantly higher relative mRNA expression of SPHK1, SPHK2, S1PR5 and S1PR2 whereas there was no increase in expression of SGPP2 and SGPL1 (n = 7experiments p<0.05, Fig 9).
*:Significant increase in mRNA expression of SPHK1, SPHK2,S1PR2, S1PR5, but no significant changes were found in SGPL1 and SGPP2 compared to non-stimulated macrophages (p<0.05).
Discussion
In recent years it has become evident that alveolar macrophages play a vital role in the pathophysiology and development of COPD [31]. Macrophages modulate and control levels of inflammation; however, the macrophage-dependent inflammatory haemostasis is defective in COPD [31]. One of the major causes of this defect is thought to be a reduced ability of alveolar macrophages to phagocytose apoptotic cells and bacteria [3,32] which contributes to ongoing inflammation in lungs of these patients [8,33]. Several studies have reported changes in candidate molecules that may at least partially contribute to the defective efferocytosis in COPD, although it is becoming clear that a more complex network of molecules rather than a single molecule is the more likely cause of the reduced efferocytosis [34,35]. In particular, identification of molecule(s) that are affected in COPD irrespective of smoking status would be an important strategy toward identification of new macrophage-targeted treatments for COPD.
Previous studies have identified the S1P system as a candidate for macrophage dysfunction. McQuiston et al. showed that the S1P-mediated increase in phagocytosis occurred in an antibody-dependent manner [23,36]. The antibody-mediated pathway is commonly linked to phagocytosis of pathogen; however, it became clear in the last decade that apoptotic cells can also become opsonized with naturally occurring IgM auto antibodies which facilitate their internalization [37–40] This mechanism is particularly efficient when combined with the complement [40]. Petrusca et al. reported that up-regulation of the S1P precursor ceramide inhibited the alveolar macrophage-mediated clearance of apoptotic cells [24]. A further study on murine microglia, resident macrophage-like cells of the CNS which are involved in phagocytosis and inflammatory responses, showed the involvement of SPHK1 signalling in their functions [41]. These studies, however, were focused on single components of the S1P system, and to the best of our knowledge, there is no study that has comprehensively studied the combination of synthesizing, degrading enzymes and receptors in human alveolar macrophages in COPD.
S1P, the product of SPHK1 and 2 has been implicated in many biological functions in the cell, including survival, proliferation and migration, and macrophage phagocytic function [16,20,42,43]. In the present study, the expression of both SPHK1 and SPHK2 mRNAs was significantly increased in alveolar macrophages from healthy smokers and current-smoker COPD subjects, with no changes found in macrophages obtained from ex-smoker COPD subjects. This indicates a close association between smoking and expression of S1P synthesizing enzymes. The effect of cigarette smoke was further highlighted by a significant increase in SPHK1 in the model of cigarette smoke-exposed THP-1 macrophages. Furthermore analysis of expression and patient data showed and a positive correlation between SPHK1 and smoking status. Smoking causes inflammation and inflammation is known to modulate SPHK1 mRNA expression in animal macrophages [41,44,45]. In this study we showed for the first time the response in SPHK1 in the context of COPD or cigarette smoking. Increased ceramide levels in alveolar macrophages have been shown to impair their ability to phagocytose apoptotic cells [24]. Ceramide is converted to sphingosine which is phosphorylated via SPHK1 and SPHK2 to S1P [46]. It is thus possible that the higher mRNA expression levels of SPHK1 or SPHK2 in alveolar macrophages in response to smoking reflect the response to high ceramide levels with the aim to reduce ceramide concentration.
A finely-tuned balance between SPHK1 and SPHK2 expression and functions, with tissue specificity has been reported [47]. For example, in rodent neuronal tissue there are higher levels of SPHK2 compared to SPHK1 [48], whereas in murine lungs there is higher expression and activity of SPHK1 [49,50]. It should be noted that the expression in the lung reflects many cell types including endothelial, epithelial cells and macrophages. Interestingly in the present study, we observed equal relative mRNA-expression levels for SPHK1 and SPHK2, and a correlation between the two in alveolar macrophages from healthy controls. In contrast, the two kinases were differentially expressed in alveolar macrophages from COPD subjects and although both SPHK1 and SPHK2 separately correlated positively with smoking status, only SPHK1 was found to be correlated with lung function suggesting a changed mRNA expression and presumably a change in balance between the kinases and the potential involvement of SPHK1 in smoking-related COPD disease progression.
S1P receptors are essential for S1P function [19]. Changes in expression of these receptors have been reported in many cell types in various lung diseases including acute lung injury, asthma, cystic fibrosis and COPD [51]. The distribution of the receptors has been shown to be cell specific and affected differently in the various disease conditions [16]. The presence of S1P receptors in macrophages has been well documented [20,52]; however, the presence and expression in human alveolar macrophages is less studied. The S1PR4 subtype showed the highest relative mRNA expression followed by the S1PR2 subtype. Consistent with our data for SPHKs, we found that expression of S1PR2 mRNA in alveolar macrophages increased with smoking, and increased in both healthy current smokers and current-smoker COPD subjects, but was unchanged in ex-smoker COPD subjects. In addition, our in vitro investigations revealed a significant increase in S1PR2 in cigarette smoke extract exposed THP-1 macrophages, confirming the direct effects of cigarette smoke on expression of this receptor. A potential role for this receptor in phagocytosis was also shown by McQuiston et al who showed that treatment with the dual S1PR2/4 antagonist JTE-013 affected the phagocytosis of Cryptococcus neoformans by wild-type alveolar macrophages in contrast with the S1PR1 antagonists W146 or VPC 23901 [23,36]. In non-alveolar macrophages/monocytes activation of S1PR2 attenuated migration [53]. This could relate to cigarette smoke-induced inhibition of macrophage function in alveoli. S1PR2 may also play a role in the activation of cytoskeletal-remodelling that occurs during efferocytosis. The increased cigarette smoke-related S1PR2 expression by alveolar macrophages found in our study was therefore surprising; however, we also noted a positive correlation between S1PR2 and S1PR4. Efferocytosis occurs with extensive pseudopod extensions and is dependent on the relative activation of Rho GTPases, Rac-1 and RhoA [54] that control actin polymerisation and formation of lamellipodia that is required for macrophage engulfment of apoptotic cells. We and others have shown that Rho activity is increased and Rac-1 activity decreased, in macrophages in response to cigarette smoke [6,55,56]. Interestingly, expression of S1PR4 protein has also been shown to activate RhoA in response to S1P stimulation in Chinese hamster ovary (CHO) cells [57], and S1P has been shown to promote migration of cells expressing S1PR4 through activation Cdc42, a Rho family member [58]. The positive correlation we found between S1PR2 and S1PR4 thus suggests that these receptors may potentially work in concert to negatively affect the efferocytosis process in response to cigarette smoke.
S1PR2 expression also induces increased macrophage accumulation in atherosclerosis plaque and promotion of inflammation in mice [59,60], and its increased expression could thus also contribute to the macrophage accumulation that has been reported in current smokers with or without COPD [61,62].
In contrast to the findings with SPHK1, SPHK2 and S1PR2, we found that S1PR5 was higher in alveolar macrophages from both ex-smoker COPD and current smoker COPD subjects and negatively correlated with both fev1 and fev/fvc indicating a possible involvement in COPD progression that is at least to some extent independent of cigarette smoking. Unlike S1PR2, there were no correlations between S1PR5 and smoking status, or with SPHK1 or SPHK2 or S1PR2. Currently, the role of S1PR5 in macrophages is unclear, although our findings of a strong negative correlation between expression of S1PR5 and phagocytosis of apoptotic cells suggest that it may play an important role in this function and contribute to the defective macrophage function in COPD. Several studies have shown that mRNA levels not always predict protein expression. We therefore utilized a functional approach to assert the increase of S1PR5 and its effects on macrophage phagocytic ability. We used a S1PR3/5 antagonist suramin [31], and found that phagocytosis was dose dependently increased with a maximum effect at 1uM suramin. Taken together with our findings of significant associations between the increased expression of SPHK, S1PR2 and S1PR5, and alveolar macrophage phagocytic ability in COPD, these data support a functional effect of the increased gene expression of S1PR5. S1PR5 has been reported to interact with Rho-G12/13 protein coupled Rho/ROCK signalling pathway in oligodendrocyte precursor cells (OPCs) and appears to mediate their migration [63]. Although we did not find significantly increased expression of S1PR1 in alveolar macrophages from either smokers or COPD subjects, this receptor was found to be strongly correlated with S1PR5. Taken together with our findings of a negative correlation with lung function and phagocytosis of apoptotic cells, these data suggest that both receptors may be associated with COPD progression and defective macrophage function in COPD either by a link between the two or common downstream effectors. Consistent with this, a previous study showed that both S1PR1 and S1PR5 enhanced microgliosis [64]. It is thus likely that the defective efferocytosis in COPD that persists despite smoke cessation could be mediated by S1PR5, possibly in association with S1PR1. Interestingly, in our previous study the relative mRNA for S1PR5 was significantly lower in whole lung tissue of patients with COPD compared to controls without COPD [16]. In the present study, however, alveolar macrophage-specific S1PR5 expression was increased when comparing COPD vs. controls. This counterintuitive finding further highlights the finely tuned balance and the tissue specificity of the sphingosine family, and stresses the need to investigate not only whole lung tissue, but individual cell types of interest.
None of the controls in this study suffered from lung cancer whereas 60% of the COPD patients did. We therefore correlated S1P system mRNA expression levels with the presence of lung cancer. The only significant correlation however was for S1PR3 that showed a positive correlation with the presence of cancer independent of COPD status, suggesting that the findings in COPD subjects in our study were not influenced by the presence of lung cancer. A potential limitation of the study is that we did not measure S1P levels in BALF as this would have provided an additional understanding of smoke- and/or COPD-related changes in S1P signalling.
S1P degradation enzymes, SGPP1, SGPP2 andSGPL1 are enzymes that metabolize S1P in the cell and their importance comes from their role in controlling the levels of S1P in the cell, excessive concentrations of which are detrimental to cell fate and functions [42,65] as well as drug resistance and cancer [66]. In the present study, SGPL1 was found to be higher in alveolar macrophages from COPD subjects while SGPP2 was higher in current-smoker COPD subjects compared to healthy controls, with a trend towards a significant correlation between SGPP2 and lung function. In parallel, we also found that cigarette smoke failed to increase mRNA levels of SGPP2 and SGPL1 in our in vitro cell line experiments. Recently, SNP variants on SGPP2 in lung epithelial cells from adult smoker subjects found to be associated with vitamin D regulations as well as and fev1 and fev/fvc ratio [67]. Furthermore, vitamin D-binding protein (DBP) levels were found to be directly responsible for alveolar macrophage activation as well as related to fev1 [68]. We also noted a non-significant trend for an increase in SGPL1, the other S1P degradation enzyme, in healthy smokers and both and current-and ex-smoker COPD subjects as well as a positive correlation with SGPP2, suggesting a link between these two enzymes in alveolar macrophages in COPD. SGPP2 converts S1P to sphingosine which can be converted back to ceramide and SGPL1 degrades S1P, which indirectly can favour an increase in ceramide over S1P, so the increase in both degradation enzymes is likely to impact on the increasing ceramide levels and subsequent defect in alveolar macrophage efferocytosis ability. In addition, the established link between COPD and vitamin D and alveolar macrophage function [69–71], and the role of these enzymes in degradation of S1P [18] suggests a potential important indirect role of SGPP2 and/or SGPL1 in the alveolar macrophage defect in COPD. Interestingly, a correlation between SGPP1 and SGPL1 expression by alveolar macrophages was found in the present study, further supporting a link between these two enzymes.
In conclusion, our data strongly support the role of the S1P signalling pathway in the defective alveolar macrophage function and resultant chronic inflammation that is present in the airways of patients with COPD. In particular, we identified S1PR5 and S1P degradation enzymes as mediators that are independently increased in alveolar macrophages in COPD, independent of the presence of cigarette smoke and, importantly, a significant correlation between S1PR5 mRNA expression and lung function. These mediators are thus worthy of their further investigation as macrophage-target therapeutic strategies for COPD and other chronic inflammatory lung diseases.
Author Contributions
Conceived and designed the experiments: JB SH HJ RH RM GH HT ER. Performed the experiments: JB. Analyzed the data: JB SH. Contributed reagents/materials/analysis tools: SH SP ER. Wrote the paper: JB SH SP HJ RH RM GH HT ER.
References
- 1. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340: 1948–1953. pmid:10379018
- 2. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS, Committee GS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care. 2001;46: 798–825. pmid:11463370
- 3. Hodge S, Hodge G, Scicchitano R, Reynolds PN, Holmes M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol. 2003;81: 289–296. pmid:12848850
- 4. Hodge S, Hodge G, Ahern J, Jersmann H, Holmes M, Reynolds PN. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2007;37: 748–755. pmid:17630319
- 5. Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178: 139–148. pmid:18420960
- 6. Hodge S, Matthews G, Dean MM, Ahern J, Djukic M, Hodge G, et al. Therapeutic role for mannose-binding lectin in cigarette smoke-induced lung inflammation? Evidence from a murine model. Am J Respir Cell Mol Biol. 2010;42: 235–242. pmid:19411612
- 7. Hodge S, Matthews G, Mukaro V, Ahern J, Shivam A, Hodge G, et al. Cigarette smoke-induced changes to alveolar macrophage phenotype and function are improved by treatment with procysteine. Am J Respir Cell Mol Biol. 2011;44: 673–681. pmid:20595463
- 8. Hart SP, Haslett C, Dransfield I. Recognition of apoptotic cells by phagocytes. Experientia. 1996;52: 950–956. pmid:8917725
- 9. Bertelmann E, Knapp S, Rieck P, Keipert S, Hartmann C, Pleyer U. Transcorneal-paracorneal penetration route for topical application of drugs to the eyt. Mycophenolate mofetil as a model substance. Ophthalmologe. 2003;100: 696–701. pmid:14504893
- 10. Hodge S, Reynolds PN. Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects. Respirology. 2012;17: 802–807. pmid:22288725
- 11. Uhlig S, Gulbins E. Sphingolipids in the lungs. Am J Respir Crit Care Med. 2008;178: 1100–1114. pmid:18755926
- 12. Kuebler WM, Yang Y, Samapati R, Uhlig S. Vascular barrier regulation by PAF, ceramide, caveolae, and NO—an intricate signaling network with discrepant effects in the pulmonary and systemic vasculature. Cell Physiol Biochem. 2010;26: 29–40. pmid:20502002
- 13. Filosto S, Castillo S, Danielson A, Franzi L, Khan E, Kenyon N, et al. Neutral sphingomyelinase 2: a novel target in cigarette smoke-induced apoptosis and lung injury. Am J Respir Cell Mol Biol. 2011;44: 350–360. pmid:20448054
- 14. Becker KA, Riethmuller J, Luth A, Doring G, Kleuser B, Gulbins E. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol. 2010;42: 716–724. pmid:19635928
- 15. Cordts F, Pitson S, Tabeling C, Gibbins I, Moffat DF, Jersmann H, et al. Expression profile of the sphingosine kinase signalling system in the lung of patients with chronic obstructive pulmonary disease. Life Sci. 2011;89: 806–811. pmid:21945191
- 16. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8: 753–763. pmid:18787560
- 17. Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol. 2011;11: 403–415. pmid:21546914
- 18. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4: 397–407. pmid:12728273
- 19. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem. 2004;92: 913–922. pmid:15258915
- 20. Weigert A, Weis N, Brune B. Regulation of macrophage function by sphingosine-1-phosphate. Immunobiology. 2009;214: 748–760. pmid:19625101
- 21. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene. 2005;24: 6314–6322. pmid:16007201
- 22. Treede I, Braun A, Sparla R, Kuhnel M, Giese T, Turner JR, et al. Anti-inflammatory effects of phosphatidylcholine. J Biol Chem. 2007;282: 27155–27164. pmid:17636253
- 23. McQuiston T, Luberto C, Del Poeta M. Role of sphingosine-1-phosphate (S1P) and S1P receptor 2 in the phagocytosis of Cryptococcus neoformans by alveolar macrophages. Microbiology. 2011;157: 1416–1427. pmid:21292747
- 24. Petrusca DN, Gu Y, Adamowicz JJ, Rush NI, Hubbard WC, Smith PA, et al. Sphingolipid-mediated inhibition of apoptotic cell clearance by alveolar macrophages. J Biol Chem. 2010;285: 40322–40332. pmid:20956540
- 25. Hodge S, Hodge G, Holmes M, Reynolds PN. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J. 2005;25: 447–454. pmid:15738287
- 26. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359: 1367–1380. pmid:18815398
- 27. Dehle FC, Mukaro VR, Jurisevic C, Moffat D, Ahern J, Hodge G, et al. Defective lung macrophage function in lung cancer +/- chronic obstructive pulmonary disease (COPD/emphysema)-mediated by cancer cell production of PGE2? PLoS One. 2013;8: e61573. pmid:23637858
- 28. Hodge SJ, Hodge GL, Holmes M, Reynolds PN. Flow cytometric characterization of cell populations in bronchoalveolar lavage and bronchial brushings from patients with chronic obstructive pulmonary disease. Cytometry B Clin Cytom. 2004;61: 27–34. pmid:15351979
- 29. Hodge S, Hodge G, Brozyna S, Jersmann H, Holmes M, Reynolds PN. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J. 2006;28: 486–495. pmid:16737992
- 30. Tran HB, Ahern J, Hodge G, Holt P, Dean MM, Reynolds PN, et al. Oxidative stress decreases functional airway mannose binding lectin in COPD. PLoS One. 2014;9: e98571. pmid:24901869
- 31. Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD. 2004;1: 59–70. pmid:16997739
- 32. Taylor AE, Finney-Hayward TK, Quint JK, Thomas CM, Tudhope SJ, Wedzicha JA, et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J. 2010;35: 1039–1047. pmid:19897561
- 33. Knapp S, Leemans JC, Florquin S, Branger J, Maris NA, Pater J, et al. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med. 2003;167: 171–179. pmid:12406830
- 34. Mukaro VR, Hodge S. Airway clearance of apoptotic cells in COPD. Curr Drug Targets. 2011;12: 460–468. pmid:20450476
- 35. Erwig LP, Henson PM. Clearance of apoptotic cells by phagocytes. Cell Death Differ. 2008;15: 243–250. pmid:17571081
- 36. McQuiston T, Luberto C, Del Poeta M. Role of host sphingosine kinase 1 in the lung response against Cryptococcosis. Infect Immun. 2010;78: 2342–2352. pmid:20194596
- 37. Hart SP, Smith JR, Dransfield I. Phagocytosis of opsonized apoptotic cells: roles for 'old-fashioned' receptors for antibody and complement. Clin Exp Immunol. 2004;135: 181–185. pmid:14738443
- 38. Peng Y, Kowalewski R, Kim S, Elkon KB. The role of IgM antibodies in the recognition and clearance of apoptotic cells. Mol Immunol. 2005;42: 781–787. pmid:15829266
- 39. Chen Y, Khanna S, Goodyear CS, Park YB, Raz E, Thiel S, et al. Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J Immunol. 2009;183: 1346–1359. pmid:19564341
- 40. Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB. IGM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity. 2005;38: 259–264. pmid:16206508
- 41. Nayak D, Huo Y, Kwang WX, Pushparaj PN, Kumar SD, Ling EA, et al. Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia. Neuroscience. 2010;166: 132–144. pmid:20036321
- 42. Blaho VA, Hla T. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev. 2011;111: 6299–6320. pmid:21939239
- 43. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, et al. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2002;54: 265–269. pmid:12037142
- 44. Fischer I, Alliod C, Martinier N, Newcombe J, Brana C, Pouly S. Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions. PLoS One. 2011;6: e23905. pmid:21887342
- 45. Hammad SM, Crellin HG, Wu BX, Melton J, Anelli V, Obeid LM. Dual and distinct roles for sphingosine kinase 1 and sphingosine 1 phosphate in the response to inflammatory stimuli in RAW macrophages. Prostaglandins Other Lipid Mediat. 2008;85: 107–114. pmid:18166496
- 46. Igarashi Y. Functional roles of sphingosine, sphingosine 1-phosphate, and methylsphingosines: in regard to membrane sphingolipid signaling pathways. J Biochem. 1997;122: 1080–1087. pmid:9498549
- 47. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem. 2005;280: 37118–37129. pmid:16118219
- 48. Blondeau N, Lai Y, Tyndall S, Popolo M, Topalkara K, Pru JK, et al. Distribution of sphingosine kinase activity and mRNA in rodent brain. J Neurochem. 2007;103: 509–517. pmid:17623044
- 49. Wadgaonkar R, Patel V, Grinkina N, Romano C, Liu J, Zhao Y, et al. Differential regulation of sphingosine kinases 1 and 2 in lung injury. Am J Physiol Lung Cell Mol Physiol. 2009;296: L603–613. pmid:19168577
- 50. Fukuda Y, Kihara A, Igarashi Y. Distribution of sphingosine kinase activity in mouse tissues: contribution of SPHK1. Biochem Biophys Res Commun. 2003;309: 155–160. pmid:12943676
- 51. Yang Y, Uhlig S. The role of sphingolipids in respiratory disease. Ther Adv Respir Dis. 2011;5: 325–344. pmid:21900155
- 52. Weigert A, Weichand B, Brune B. S1P regulation of macrophage functions in the context of cancer. Anticancer Agents Med Chem. 2011;11: 818–829. pmid:21707489
- 53. Weichand B, Weis N, Weigert A, Grossmann N, Levkau B, Brune B. Apoptotic cells enhance sphingosine-1-phosphate receptor 1 dependent macrophage migration. Eur J Immunol. 2013;43: 3306–3313. pmid:23934754
- 54. Ndozangue-Touriguine O, Hamelin J, Breard J. Cytoskeleton and apoptosis. Biochem Pharmacol. 2008;76: 11–18. pmid:18462707
- 55. Richens TR, Linderman DJ, Horstmann SA, Lambert C, Xiao YQ, Keith RL, et al. Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA. Am J Respir Crit Care Med. 2009;179: 1011–1021. pmid:19264974
- 56. Mukaro VR, Bylund J, Hodge G, Holmes M, Jersmann H, Reynolds PN, et al. Lectins offer new perspectives in the development of macrophage-targeted therapies for COPD/emphysema. PLoS One. 2013;8: e56147. pmid:23441163
- 57. Graler MH, Grosse R, Kusch A, Kremmer E, Gudermann T, Lipp M. The sphingosine 1-phosphate receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13. J Cell Biochem. 2003;89: 507–519. pmid:12761884
- 58. Kohno T, Matsuyuki H, Inagaki Y, Igarashi Y. Sphingosine 1-phosphate promotes cell migration through the activation of Cdc42 in Edg-6/S1P4-expressing cells. Genes Cells. 2003;8: 685–697. pmid:12875654
- 59. Skoura A, Michaud J, Im DS, Thangada S, Xiong Y, Smith JD, et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31: 81–85. pmid:20947824
- 60. Wang F, Okamoto Y, Inoki I, Yoshioka K, Du W, Qi X, et al. Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice. J Clin Invest. 2010;120: 3979–3995. pmid:20978351
- 61. Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med. 2001;164: 469–473. pmid:11500352
- 62. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med. 1995;152: 1666–1672. pmid:7582312
- 63. Novgorodov AS, El-Alwani M, Bielawski J, Obeid LM, Gudz TI. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J. 2007;21: 1503–1514. pmid:17255471
- 64. Miron VE, Ludwin SK, Darlington PJ, Jarjour AA, Soliven B, Kennedy TE, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol. 2010;176: 2682–2694. pmid:20413685
- 65. Morales A, Lee H, Goni FM, Kolesnick R, Fernandez-Checa JC. Sphingolipids and cell death. Apoptosis. 2007;12: 923–939. pmid:17294080
- 66. Oskouian B, Saba JD. Cancer treatment strategies targeting sphingolipid metabolism. Adv Exp Med Biol. 2010;688: 185–205. pmid:20919655
- 67. Reardon BJ, Hansen JG, Crystal RG, Houston DK, Kritchevsky SB, Harris T, et al. Vitamin D-responsive SGPP2 variants associated with lung cell expression and lung function. BMC Med Genet. 2013;14: 122. pmid:24274704
- 68. Wood AM, Bassford C, Webster D, Newby P, Rajesh P, Stockley RA, et al. Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax. 2011;66: 205–210. pmid:21228423
- 69. Chishimba L, Thickett DR, Stockley RA, Wood AM. The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax. 2010;65: 456–462. pmid:20435872
- 70. Parekh D, Thickett DR, Turner AM. Vitamin D deficiency and acute lung injury. Inflamm Allergy Drug Targets. 2013;12: 253–261. pmid:23782208
- 71. Romme EA, Smeenk FW, Rutten EP, Wouters EF. Osteoporosis in chronic obstructive pulmonary disease. Expert Rev Respir Med. 2013;7: 397–410. pmid:23952337